In Brief: Medtronic
This article was originally published in The Gray Sheet
Medtronic: Purchases worldwide manufacturing and distribution rights to Germany-based Tricumed's IP-20.1 fixed-rate and IP-35.1 selectable rate drug pumps and related accessories. The implantable pumps will complement Medtronic's SynchroMed pump, which is a higher-end device that can be reprogrammed after implantation through telemetry. Medtronic will continue selling the Tricumed pumps in Europe through Tricumed's distribution network but eventually plans to use its own direct European sales force...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.